drugset
drugset / Trial / NCT05312567

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

NCT05312567 ↗

Phase 2 Completed 105 enrolled Fervent Pharmaceuticals ICON plc · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase II proof of concept study is designed to assess the safety and efficacy of FP-101 (60mg b.i.d.), an extended-release oral tablet product, compared to a matching placebo in the treatment of moderate-to-severe hot flashes in peri- and post-menopausal women over a period of 1-week.

Timeline

Start
2021-03-24
Primary completion
2023-04-05
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject FP-101 Unknown 60 mg Oral

Indications

No indication recorded.